Sunicent 50 mg | Generic Sunitinib by Incepta Pharmaceuticals

Description

Dr. Daria KwaśniewskaESMO Certified Consultant Medical Oncologist

Reviewed June 2026

⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid oncologist prescription is mandatory before any order is processed.

Is Sunicent 50 mg right for your situation?

Review these criteria with your oncologist before enquiring

✔ You may be a candidate if

✓Diagnosed with advanced or metastatic renal cell carcinoma (RCC)
✓High-risk of RCC recurrence after nephrectomy, prescribed adjuvant therapy
✓GIST that has progressed on or is intolerant to imatinib
✓Seeking a WHO-GMP certified generic Sunitinib by Incepta Pharmaceuticals

✖ May NOT be suitable if

✗Uncontrolled hypertension or history of heart failure
✗QT prolongation or on medications that prolong QT interval
✗Pregnant, planning pregnancy, or breastfeeding
✗Recent major surgery or wound not yet healed

Check Availability & Pricing

Prescription required · Named Patient Program · Worldwide shipping

💬 WhatsApp: +880 130 449 8958 ✉ Email: info@medsforcancer.com

🛡 WHO-GMP Certified · Prescription verified · Express dispatch

What is Sunicent 50 mg?

Sunicent 50 mg is a generic hard capsule formulation of Sunitinib (as sunitinib malate) — a multi-targeted receptor tyrosine kinase inhibitor — manufactured by Incepta Pharmaceuticals Ltd., a WHO-GMP certified pharmaceutical company based in Bangladesh. Each capsule contains 50 mg of sunitinib, the same active molecule as in Sutent® (Pfizer), and is dispensed under the Named Patient Program.

The FDA approved sunitinib for adjuvant treatment of high-risk RCC following nephrectomy in November 2017, in addition to its original approvals for advanced RCC and imatinib-resistant GIST.

Generic name	Sunitinib (as sunitinib malate)
Reference brand	Sutent® (Pfizer)
Manufacturer	Incepta Pharmaceuticals Ltd.
Standard	WHO-GMP Certified
Drug class	Multi-targeted RTK Inhibitor (VEGFR, PDGFR, KIT, FLT3, RET)
Dosage form	Hard capsule — 50 mg
Pack size	12 capsules (3 strips of 4)
Route	Oral · once daily, with or without food
Prescription	Required — oncologist only

How Sunitinib Works

Tumours depend on angiogenesis — forming new blood vessels — to receive the oxygen and nutrients needed for growth, and on aberrant kinase signalling to drive uncontrolled cell division.

Sunitinib simultaneously inhibits multiple receptor tyrosine kinases, including VEGFR-1, -2, -3, PDGFR-α/β, KIT, FLT3, RET, and CSF-1R. By blocking VEGF and PDGF receptor signalling, it starves tumours of their blood supply while directly inhibiting KIT-driven proliferation in GIST. This dual anti-angiogenic and anti-proliferative action can shrink tumours and slow disease progression across its approved indications.

What to Expect: First 30 Days

Sunicent is taken in a 4-weeks-on, 2-weeks-off cycle for RCC and GIST — understanding this rhythm helps set expectations for side effects and recovery windows.

Before starting: baseline blood pressure, ECG, thyroid function, and liver function tests are required.
Week 1–2: Fatigue, taste changes, and mild gastrointestinal upset are common as the body adjusts.
Weeks 3–4: Blood pressure and blood counts are monitored closely; hand-foot skin reactions may appear.
Weeks off (5–6): Many side effects ease during the 2-week break before the next cycle begins.

Side Effects

Most side effects follow the on/off treatment rhythm and are most noticeable during the 4 weeks on-treatment. Always report new or worsening symptoms to your oncologist.

Common · Usually Manageable

Fatigue and weakness
Diarrhoea, nausea, vomiting
Taste changes, mouth sores
Hand-foot syndrome
High blood pressure
Decreased appetite

Serious · Report Immediately

Liver toxicity, including rare liver failure
Heart failure or LVEF decline
QT prolongation / abnormal heart rhythm
Serious bleeding or GI perforation
Thyroid dysfunction

⚠ Go to A&E or call your doctor immediately if you experience:

Yellowing of skin/eyes, dark urine, or severe abdominal pain
Shortness of breath, swelling of feet/ankles, or irregular heartbeat
Unexplained bleeding or blood in stool/urine

How to Take Sunicent 50 mg

Standard dose for RCC and GIST: 50 mg once daily for 4 weeks, followed by 2 weeks off (repeating 6-week cycles). Adjuvant RCC follows the same 4/2 schedule for nine cycles. With or without food, same time each day.

1
Swallow whole with a glass of water — with or without food.
2
Keep to the 4-weeks-on/2-weeks-off schedule exactly as prescribed — do not extend or shorten either period without your oncologist’s guidance.
3
If you miss a dose, take it as soon as remembered unless it is close to the next scheduled dose — never double up.
4
Tell your surgical team if any procedure is planned — sunitinib impairs wound healing and is usually paused before and after surgery.

Caregiver Guidance

♥
Check blood pressure regularly — sunitinib-induced hypertension is common and needs consistent monitoring, especially during on-treatment weeks.
♥
Watch hands and feet for redness, pain, or blistering (hand-foot syndrome) — early reporting allows dose adjustment before it becomes severe.
♥
Track energy and appetite across the treatment cycle — significant changes are worth flagging at the next oncology visit.

If the Disease Continues to Progress

If RCC or GIST progresses despite sunitinib, your oncologist will typically reassess with updated imaging and may switch to a different targeted agent (such as pazopanib, cabozantinib, or axitinib for RCC, or regorafenib for imatinib/sunitinib-resistant GIST) or consider immunotherapy combinations depending on your specific cancer type and prior treatment history.

Frequently Asked Questions

Who manufactures Sunicent and is it reliable?

Sunicent is manufactured by Incepta Pharmaceuticals Ltd., a WHO-GMP certified pharmaceutical company based in Bangladesh with export certification supplying generic oncology medicines across Asia, the Middle East, and Africa under Named Patient Program frameworks.

Why is treatment given in a 4-weeks-on, 2-weeks-off cycle?

This schedule was established in the pivotal clinical trials to balance effective tumour control against cumulative toxicity. The 2-week break allows the body to recover between treatment periods and is not optional — do not continue dosing through the off-weeks unless specifically instructed by your oncologist.

How does Sunicent compare to Sutent®?

Both contain sunitinib 50 mg as the active ingredient targeting the same multi-kinase mechanism. Sunicent is manufactured under WHO-GMP certified conditions ensuring consistent potency and purity, at substantially lower cost than the branded originator. Clinical decisions on equivalence should always involve your treating oncologist.

How do I order Sunicent through Meds For Cancer?

Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist’s prescription. Our team will review it, confirm availability and pricing for your country, and arrange secure international dispatch under the Named Patient Program.

🛡 Named Patient Program — Regulatory Framework

Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid oncologist prescription, in countries where the branded product is unavailable or unaffordable.

This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.

Clinical References

Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. NEJM 2007;356:115–124.
Ravaud A, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma. NEJM 2016;375:2246–2254.
Demetri GD, et al. Efficacy and safety of sunitinib in GIST after imatinib failure. Lancet 2006;368:1329–1338.
FDA Prescribing Information: Sutent (sunitinib malate). Pfizer, 2017.